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Alzheimer’s disease (AD), the most common form of dementia, is
characterized by the abnormal accumulation of amyloid plaques
and hyperphosphorylated tau aggregates, as well as microgliosis.
Hemizygous missense variants in Triggering Receptor Expressed
on Myeloid Cells 2 (TREM2) are associated with elevated risk for
developing late-onset AD. These variants are hypothesized to
result in loss of function, mimicking TREM2 haploinsufficiency.
However, the consequences of TREM2 haploinsufficiency on tau
pathology and microglial function remain unknown. We report
the effects of partial and complete loss of TREM2 on microglial
function and tau-associated deficits. In vivo imaging revealed
that microglia from aged TREM2-haploinsufficient mice show a
greater impairment in their injury response compared with micro-
glia from aged TREM2-KO mice. In transgenic mice expressing
mutant human tau, TREM2 haploinsufficiency, but not complete
loss of TREM2, increased tau pathology. In addition, whereas
complete TREM2 deficiency protected against tau-mediated
microglial activation and atrophy, TREM2 haploinsufficiency ele-
vated expression of proinflammatory markers and exacerbated
atrophy at a late stage of disease. The differential effects of partial
and complete loss of TREM2 on microglial function and tau pathol-
ogy provide important insights into the critical role of TREM2 in
AD pathogenesis.
inflammation | motility | neurodegeneration | tau inclusions | RNA-seq
Alzheimer’s disease (AD), the most common form of de-mentia, is characterized pathologically by the abnormal
accumulation of amyloid plaques, hyperphosphorylated tau ag-
gregates, and microgliosis. The recent genetic implication of a
microglial-expressed gene, Triggering Receptor Expressed on
Myeloid Cells 2 (TREM2), in late-onset AD suggests a pivotal
role for microglia in AD pathogenesis. Although mutations in
TREM2 are rare, this gene is nonetheless the strongest immune
gene-specific risk factor for AD discovered thus far (1–3).
TREM2 encodes a transmembrane receptor that is expressed by
microglia in the brain (4, 5). TREM2 has been implicated in
neuroinflammation and in the metabolic fitness, proliferation,
survival, and phagocytic capacity of microglia (6–16).
The most common AD-associated TREM2 variant, R47H, is
associated with an approximately threefold increased risk for
developing late-onset AD (1–3). It is thought to result in a
TREM2 loss-of-function phenotype (10, 17, 18). Compared
with noncarriers, R47H carriers have higher levels of phos-
phorylated tau around plaques (19) and more neurofibrillary
tangles (20). In addition, R47H carriers have higher levels of
cerebrospinal fluid (CSF)-soluble TREM2, and CSF-soluble
TREM2 levels were significantly correlated with higher levels
of CSF-phosphorylated tau (21). These observations in hu-
man patients suggest a detrimental effect of TREM2 hap-
loinsufficiency on tau pathology. Surprisingly, in a tauopathy
mouse model, complete loss of TREM2 function had no effect
on tau pathology, while protecting against brain atrophy (22).
These findings highlight the need to assess the effects of TREM2
haploinsufficiency in AD models.
We investigated how TREM2 haploinsufficiency, a model
relevant to AD cases carrying hemizygous risk variants, affects
microglial function and tau pathology. By using in vivo two-
photon microscopy to visualize microglial motility, we found
that TREM2 haploinsufficiency resulted in an age-dependent
impairment in microglial injury response without affecting
baseline motility. Interestingly, complete loss of TREM2
resulted in a milder impairment in injury-induced motility
compared with TREM2 haploinsufficiency. We then investi-
gated the effects of TREM2 haploinsufficiency and complete
deficiency on tau pathology in mice expressing mutant human
tau (P301S). Our findings demonstrated a robust increase in
tau pathology in TREM2-haploinsufficient mice, an effect that
was not observed in TREM2-KO mice. We further investi-
gated how TREM2 haploinsufficiency and complete defi-
ciency affect tau-mediated deficits.
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Late-onset Alzheimer’s disease is the most common form of
dementia. A rare hemizygous variant in a microglial-expressed
gene, Triggering Receptor Expressed on Myeloid Cells 2
(TREM2), significantly increases risk for late-onset Alzheimer’s
disease. This variant is thought to cause loss of function, in-
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haploinsufficiency on microglial function and tau pathology
are major gaps in the field. We find that, in contrast to the
protective effects of complete TREM2 deficiency, TREM2 hap-
loinsufficiency exacerbates tau pathology, inflammation, and
atrophy at a late stage of disease in a mouse model of tau-
opathy. The differential effects of partial and complete loss of
TREM2 are important considerations for TREM2-targeted ther-
apeutic strategies.
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Results
TREM2 Haploinsufficiency Causes an Age-Dependent Impairment in
Microglia’s Injury Response. Microglia carry out critical functions
of surveying the brain and responding to injury (23, 24). To
address the effect of TREM2 on microglial surveillance, we used
in vivo two-photon imaging to examine microglial motility in 3–
5-mo-old TREM2+/+, TREM2+/− and TREM2−/− mice crossed to
Cx3cr1GFP/+ mice, in which microglia express enhanced GFP
driven by the Cx3cr1 promoter (25). Analysis of a 10-min time-
lapse recording of cortical microglia showed no differences in the
baseline properties of microglia across the three genotypes, in-
cluding average speed of process extension and retraction and
total change in process length (Fig. 1 A and B). TREM2 also had
no effect on microglial cell density or cell body size at baseline
(SI Appendix, Fig. S1 A and B). Moreover, in response to a laser-
induced focal tissue injury, microglia from young TREM2+/+,
TREM2+/− and TREM2−/− mice exhibited no difference in cell
density (Fig. 1C), cell body size (SI Appendix, Fig. S1C), or the
density of microglial processes extending toward the injury site
(Fig. 1 D and E and Movie S1).
Given the established association of TREM2 with age-related
diseases (1–3, 26), we next examined the effects of TREM2 on
microglial motility in 9–14-mo-old TREM2+/+, TREM2+/− and
TREM2−/− mice. At baseline, the average speed and total change
in process length did not differ across genotypes (Fig. 1 F and G).
Microglial cell density or cell body size also remained similar (SI
Appendix, Fig. S1 D and E). Strikingly, in response to focal tissue
injury, microglia from older TREM2+/− mice exhibited a signifi-
cantly reduced response to injury compared with WT microglia, as
evidenced by fewer microglial processes extending toward the site
of injury at any given time point (Fig. 1 I and J and Movie S2).
TREM2−/− microglia showed a significant, yet milder, attenuation
in response size compared with TREM2+/− (Fig. 1 I and J and
Movie S2). TREM2+/− microglia were the slowest to respond,
extended the fewest processes toward the site of injury, and did
not reach the injury site within 60 min (Fig. 1I and Movie S2).
TREM2−/− microglia, on the contrary, were able to reach the in-
jury site within 60 min, similar to WTmicroglia (Fig. 1I and Movie
S2). The impairment in TREM2+/− and TREM2−/− microglia re-
sponses were not associated with differences in microglial density
(Fig. 1H) or activation state, as evidenced by the unaltered cell
body size (SI Appendix, Fig. S1F). Moreover, there was no cor-
relation between ablation size and response (SI Appendix, Fig.
S1G), indicating that the reduced response sizes in TREM2-
deficient microglia were not caused by smaller injuries. Thus,
surprisingly, TREM2 haploinsufficiency attenuates the in vivo
microglial response to tissue injury in an age-dependent manner
and to a greater extent than complete TREM2 deficiency.
TREM2 Haploinsufficiency and Complete Deficiency Differentially
Regulate the Microglial Transcriptome in the Presence and Absence
of Tauopathy. Next, to identify microglial pathways regulated by
TREM2 in an unbiased fashion, we performed RNA sequencing
(RNA-seq) of adult microglia isolated by using CD11b magnetic
beads from young TREM2+/+, TREM2+/− and TREM2−/− mice.
We confirmed the purity of our adult-isolated microglia, as their
transcriptome closely matched a previously published microglial
transcriptome (27) (Fig. 2A). TREM2 haploinsufficiency and
complete deficiency altered the microglial transcriptome in
unique ways (Fig. 2B). A total of 107 transcripts were significantly
different between TREM2+/− and TREM2−/− (Fig. 2C). Ingenuity
Pathway Analysis (IPA) revealed cellular movement as the most
significantly altered biological pathway in TREM2+/− microglia
compared with TREM2−/− (Fig. 2D), consistent with our in vivo
imaging finding that TREM2+/− microglia exhibited greater im-
pairment in their injury response than TREM2−/− (Fig. 1J). In-
terestingly, these transcriptomic alterations in young TREM2+/−
microglia preceded the impaired injury response seen in aged
TREM2+/− microglia. In addition, multiple pathways pertaining
to inflammation were significantly altered between TREM2+/−
and TREM2−/− microglia, such as immune cell trafficking and
inflammatory response (Fig. 2D), suggesting differential regula-
tion of inflammation in TREM2+/− vs. TREM2−/− microglia.
The rare R47H missense variant in TREM2 is associated with
increased risk for tauopathies (2, 3, 26, 28) and hyperphosphorylation
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Fig. 1. TREM2 haploinsufficiency causes an age-dependent impairment of
microglia’s injury response in vivo. (A–E) Quantification of microglial motility
in 3–5-mo-old mice. Quantification of the average speed per microglial
process (A) and total change in length of microglial processes (B) during
10-min baseline recordings from 3–5-mo-old mice. TREM2+/+, n = 7 record-
ings from 7 mice; TREM2+/−, n = 9 recordings from 9 mice; TREM2−/−, n = 10
recordings from 10 mice. (C) Microglial density for young mice from laser-
induced tissue injury videos. TREM2+/+, n = 10 recordings from 9 mice;
TREM2+/−, n = 11 recordings from 10 mice; TREM2−/−, n = 12 recordings from
10 mice. (D) Representative still images at 3 min, 21 min, 39 min, and 57 min
from the microglial responses to injury in young mice. Laser ablations are
outlined with smaller white circles. The response was normalized to micro-
glial density at each time point, denoted by larger white circles. (Scale bar:
20 μm.) (E) Quantification of normalized microglial responses from young
mice toward focal laser-induced tissue injury over a period of 60 min from
time of injury. TREM2+/+, n = 7 injuries from 7 mice; TREM2+/−, n = 11 injuries
from 10 mice; TREM2−/−, n = 12 injuries from 10 mice. (F–H) Quantification of
microglial motility in 9–14-mo old mice. (F) Quantification of the average
speed per microglial process and (G) total change in length of processes
during 10-min baseline recordings from 9–14-mo-old mice. TREM2+/+, n = 10
recordings from 7 mice; TREM2+/−, n = 10 recordings from 9 mice; TREM2−/−,
n = 10 recordings from 9 mice. (H) Microglial density for aged mice during
laser-induced tissue injury experiments. TREM2+/+, n = 7 recordings from 6
mice; TREM2+/−, n = 13 recordings from 10 mice; TREM2−/−, n = 12 recordings
from 9 mice. (I) Representative still images at 3 min, 21 min, 39 min, and
57 min from the microglial responses to injury in aged mice. Laser ablations
are outlined with smaller white circles. Response size was normalized to
microglial density at each time point, denoted by larger white circles. (Scale
bar: 20 μm.) (J) Quantification of normalized microglial responses from aged
mice toward focal laser-induced tissue injury was measured over a period of
60 min from time of injury. TREM2+/+, n = 6 injuries from 5 mice; TREM2+/−,
n = 13 injuries from 10 mice; TREM2−/−, n = 12 injuries from 9 mice (****P <
0.0001, STATA mixed-effects modeling). Values are expressed as mean ±
SEM. Data were analyzed using one-way ANOVA with Bonferroni post hoc
analyses for all panels except for E and J, which were analyzed by using
STATA mixed-effects modeling.
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of tau in AD carriers (19). We next investigated how TREM2
affects tau pathology and tau-associated deficits in the P301S
tauopathy mouse model (Prnp-MAPT*P301S) (29). The effects of
TREM2 haploinsufficiency and complete loss of TREM2 on tau-
induced transcriptional changes were examined at 8–9 mo of age
(SI Appendix, Fig. S2A), when P301S mice exhibit significant tau
inclusions, microgliosis, and neuronal loss (29). Compared with
P301S+ TREM2+/+ mice, there were 232 differentially expressed
transcripts in P301S+ TREM2+/− mice (Fig. 3A). These transcripts
were significantly enriched for pathways pertaining to microglial
development, such as TGFβ signaling (4), and inflammation, such
as IL2 STAT5 signaling and TNF-α signaling via NF-κB (SI Ap-
pendix, Fig. S2B). To validate these pathways, we performed
quantitative real-time PCR of pro- and anti-inflammatory mark-
ers. Consistent with tau-mediated inflammatory responses, ex-
pression of P301S human tau significantly increased levels of
proinflammatory cytokines TNF-α, IL-1α, and IL-1β (SI Appendix,
Fig. S3). Importantly, TREM2+/− resulted in significantly elevated
levels of TNF-α and IL-1α compared with P301S+ TREM2+/+
mice, but had no effects on anti-inflammatory markers VEGF1,
Cox2, or IL-34 (SI Appendix, Fig. S3). Differentially expressed
genes in P301S+ TREM2−/− on the contrary, were significantly
enriched for genes related to metabolism, such as oxidative
phosphorylation, glycolysis, and MTORC1 signaling (SI Appendix,
Fig. S2C). Direct comparison of P301S+ TREM2+/− and P301S+
TREM2−/− revealed that, of the 389 differentially expressed
transcripts, there was a significant enrichment of complement-
related genes and inflammatory response genes (Fig. 3B).
TREM2 Haploinsufficiency Exacerbates Tau Pathology in P301S Mice.
We then assessed how partial and complete loss of TREM2 af-
fects tau aggregation. Immunohistochemistry with the AT8 anti-
body, which recognizes two phosphorylation sites on tau (pS202,
pT205), revealed a significant increase in the AT8+ area in the
cortex of P301S+ TREM2+/− mice compared with P301S+
TREM2+/+ and P301S+ TREM2−/− (Fig. 4 A and B) and a trend
toward increased AT8 pathology in the hippocampus (Fig. 4 C
and D). In contrast, there was no difference in AT8 load between
P301S+ TREM2−/− and P301S+ TREM2+/+ mice in hippocampus
and cortex (Fig. 4 A–D), consistent with a recent finding by Leyns
et al. (22). We also performed immunohistochemistry with the
MC1 antibody, which detects a pathological conformation of tau
(30). Consistent with the differential effects induced by TREM2+/−
and TREM2−/− on AT8 pathology, P301S+ TREM2+/− mice had
significantly greater MC1+ area than P301S+ TREM2−/− in cortex
(Fig. 4 E and F) and in hippocampus (Fig. 4 G and H). Similarly,
the MC1+ area in the hippocampus of P301S+ TREM2+/− mice,
most notably in the mossy fibers, was significantly greater than in
P301S+ TREM2+/+ mice (Fig. 4 G and H). A similar trend was
observed in the cortex (Fig. 4 E and F). In sharp contrast, the
MC1+ area trended toward a decrease in P301S+ TREM2−/− mice
compared with P301S+ TREM2+/+ mice (Fig. 4 F and H). Thus,
TREM2 haploinsufficiency, but not complete loss of TREM2,
enhances tau pathology.
Differential Effects of Partial and Complete TREM2 Deficiency on
Atrophy and Microgliosis in P301S Mice. Next, we investigated
how TREM2 haploinsufficiency and complete deficiency affect
tau-induced neurodegeneration. At 8–9 mo of age, there were
similar levels of hippocampal neuronal loss in P301S mice re-
gardless of TREM2 genotype (SI Appendix, Fig. S4 A and B) and
tau-induced atrophy could not yet be detected in cortex (SI
Appendix, Fig. S4C). However, complete TREM2 deficiency
resulted in a protection against hippocampal atrophy, as evidenced
by the smaller lateral ventricle area (Fig. 5 A and B), and a trend
toward increased hippocampal area (Fig. 5C). This result is in
agreement with a previous report that showed that complete
TREM2 deficiency protected against brain atrophy in P301S
mice (22). Compared with P301S+ TREM2+/+, TREM2 hap-
loinsufficiency did not significantly affect atrophy at 8–9 mo (Fig. 5
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A–C) or at 10–11 mo of age (Fig. 5 D and E). However, compared
with WT mice, P301S+ TREM2+/−, but not P301S+ TREM2+/+,
mice exhibited significantly more severe atrophy (Fig. 5 D and E).
We next evaluated how TREM2 levels affect tau-induced
microgliosis, a canonical hallmark of AD pathology recapitulated
in P301S mice (29). Analysis of Iba1 immunoreactivity in the
hippocampus revealed an expected significant increase in micro-
glial number induced by P301S tau (Fig. 6 A and B). Interestingly,
compared with P301S+ TREM2+/+, complete TREM2 deficiency,
but not haploinsuffciency, resulted in a trend toward reduced
microglial density (Fig. 6 A and B). Moreover, the number of
microglia positively correlated with MC1+ area (Fig. 6C), sup-
porting the idea that elevated tau pathology is associated with
inflammatory responses in microglia.
To further characterize how TREM2 levels affect tau-mediated
microglial activation, we performed morphological analyses by
using 3D renderings of confocal images (Fig. 6D). Compared with
TREM2+/+, TREM2 haploinsufficiency in P301S mice induced
significantly shortened processes (Fig. 6E) and fewer branches
(Fig. 6F), indicating strong tau-mediated microglial activation. In
contrast, complete loss of TREM2 in P301S mice resulted in a
failure to induce morphological changes associated with microglial
activation; microglia from P301S+ TREM2−/− mice exhibited
similar process length and arborization as nonactivated microglia
from WT (TREM+/+) mice (Fig. 6 D–F).
Discussion
Our study highlights multiple findings in which TREM2 hap-
loinsufficiency resulted in stronger or different phenotypes than
complete TREM2 deficiency. TREM2 haploinsufficiency led to
a greater age-dependent impairment in microglia response to
injury compared with complete TREM2 deficiency. Moreover,
TREM2 haploinsufficiency exacerbated tau pathology, atrophy,
and inflammation. On the contrary, complete loss of TREM2
protected against atrophy and reduced microgliosis. Interest-
ingly, complete loss of TREM2 was also associated with trends
toward reduced MC1+ pathology. These results highlight multiple
TREM2 phenotypes that are gene-dose–independent. As hemi-
zygous TREM2 variants are associated with elevated risk for AD,
TREM2 haploinsufficiency may be a more relevant model to
study how TREM2 contributes to AD pathogenesis. Indeed,
complete loss of TREM2 in humans results in Nasu–Hakola
disease (31), which could be driven by mechanisms that are dis-
tinct from those of AD.
As the resident immune cells in the brain, microglia need to
respond robustly to injury, especially in neurodegenerative brains
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P301S+ TREM2−/−, n = 10 mice; 6–8 sections per mouse. (E) Representative
images of MC1 immunostaining in the cortex of 8–9-mo-old mice. (Scale
bar: 300 μm.) (F) Quantification of the percentage of MC1+ area in the
cortex of P301S+ TREM2+/+, n = 9 mice; P301S+ TREM2+/−, n = 25 mice;
P301S+ TREM2−/−, n = 9 mice; 7–16 sections per mouse (**P < 0.01, R mixed-
effects modeling). (G) Representative images of MC1 immunostaining in
the hippocampus of 8–9-mo-old mice. (Scale bar: 100 μm.) (H) Quantifica-
tion of the percentage of MC1+ area in the hippocampus of P301S+
TREM2+/+, n = 9 mice; P301S+ TREM2+/−, n = 25 mice; P301S+ TREM2−/−, n =
10 mice; 7–16 sections/mouse (**P < 0.01, ***P < 0.001, R mixed-effects
modeling). Values are expressed as mean ± SEM.
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that have increased neuronal death and accumulation of abnormal
protein aggregates. By using in vivo imaging, we showed that
TREM2 haploinsufficiency impairs microglia’s injury-induced re-
sponse in an age-dependent manner and to a greater degree than
complete loss of TREM2 (Fig. 1J and Movie S2). It is interesting
that this result is present in aged but not young mice. This finding
mirrors the role of TREM2 in the development of late-onset AD.
Notably, there was no impairment in baseline motility (Fig. 1 F
and G), suggesting that TREM2 modulates microglial pathways
specifically related to injury response. This injury-specific modu-
lation of motility may contribute to TREM2’s implication in
neurodegeneration, in which neuronal injury is abundant. This
type of differential modulation of baseline and injury-induced
motility has been observed previously in the microglia field. For
example, the purinergic receptor P2RY12 was found to slow down
microglia’s response to ATP/ADP released during injury without
affecting baseline motility (32).
Aged TREM2-haploinsufficient microglia were significantly
slower to respond to injury and extended fewer processes toward
the site of injury throughout the 60-min imaging session (Movie
S2). Interestingly, TREM2-deficient microglia showed an in-
termediate phenotype between TREM2 haploinsufficient and WT
microglia. On average, they extended more processes toward the
site of injury than TREM2-haploinsufficient microglia, and they
were able to reach the site of injury within 60 min (Movie S2).
This gene-dose–independent phenomenon may be driven by
compensatory mechanisms in microglia completely lacking
TREM2 from development, whereas TREM2 haploinsufficiency
could elicit different types of compensatory changes via modula-
tion of TREM2 expression from the existing allele. Our RNA-seq
analyses of TREM2+/− and TREM2−/− microglia revealed a sig-
nificant difference in the cellular movement pathway induced by
TREM2 deficiency (Fig. 2D), consistent with a previous study that
looked at TREM2+/+ and TREM2−/− microglia (33). Interestingly,
the transcriptional changes in TREM2-haploinsufficient microglia
occurred before the development of the impaired injury response.
These observations are consistent with a two-hit hypothesis: young
TREM2-haploinsufficient microglia can maintain normal function,
but those challenged by age or pathological conditions, such as
tauopathy, are unable to do so.
Remarkably, TREM2 haploinsufficiency exacerbated tau pa-
thology whereas complete TREM2 deficiency did not (Fig. 4),
yet another phenotype that was not gene-dose–dependent. Of
note, patients with the R47H TREM2 variant have increased tau
pathology (13), similar to TREM2-haploinsufficient tauopathy
mice. One likely explanation for the lack of effect of complete
TREM2 deficiency on multiple phenotypes is that complete loss
of TREM2 may result in compensatory changes. Indeed, a pre-
vious study showed that, in the absence of TREM2, expression of
homeostatic microglial genes was not suppressed, but rather fully
preserved and even slightly increased, supporting the possibility
of compensation (33). Moreover, we observed transcriptional
changes between TREM2+/− and TREM2−/− microglia that may
underlie gene-dose–independent phenotypes. Inflammatory path-
ways were altered at the transcriptional level between TREM2+/−
and TREM2−/− microglia from young mice (Fig. 2D), highlighting
early-onset, inherent TREM2-dependent changes in microglial ac-
tivation that persisted in older disease states (Fig. 6 and SI Ap-
pendix, Fig. S3).
The P301S mouse model begins to show neuronal loss at 9–
10 mo of age (29). Neither TREM2 haploinsufficiency nor complete
deficiency exacerbated neuronal loss at 8–9 mo of age. However,
complete loss of TREM2 protected against tau-induced atrophy
(Fig. 5 A–C). Our results suggest that the increase in cortical
volume seen by Leyns et al. (22) may not be caused by a pro-
tection against neuronal loss per se, as P301S+ TREM2−/− mice
had a similar number of neurons as P301S+ TREM2+/+ mice (SI
Appendix, Fig. S4C). Instead, complete loss of TREM2 may in-
crease cortical volume through other mechanisms, such as pro-
tection against loss of neuronal processes or, given TREM2’s
implication in lipid sensing (10), through an increase in the
brain’s lipid content. In contrast to the neuroprotective effect of
complete loss of TREM2, partial loss of TREM2 appears to be
detrimental, highlighted by the significant increase in lateral
ventricle area at 10–11 mo of age compared with WT mice (Fig.
5E). It is interesting to note that complete loss of TREM2
resulted in a trend toward reduced late-stage tau pathology and
reduced atrophy, whereas TREM2 haploinsufficiency exacer-
bated tau pathology and exacerbated atrophy. It remains to be
determined whether tau pathology and microglial activation
work together or independently to cause brain atrophy.
We also detected increased expression of proinflammatory
cytokines in P301S+ TREM2+/− mice (SI Appendix, Fig. S3), a
finding consistent with the cytokine profiles in R47H carriers with
AD (20). However, it is unclear whether the increased in-
flammatory state is a cause or consequence of the increased tau
pathology present in TREM2+/− mice and patients with the R47H
variant (19). Interestingly, in amyloid mouse models, TREM2
haploinsufficiency did not affect the expression of pro- or anti-
inflammatory markers at early or later stages of amyloid pathol-
ogy (8), but reduced microglia number (10). These studies, in
conjunction with our data, suggest that TREM2 haploinsufficiency
differentially modulates inflammation in the contexts of amyloid and
tau pathology. On the contrary, P301S+ mice completely lacking
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Fig. 6. Differential regulation of inflammation by partial and complete loss
of TREM2 in P301S+mice. (A) Representative images of Iba1 immunostaining
of microglia in the hippocampus of 8–9-mo-old mice. (Scale bar: 300 μm.) (B)
Quantification of the number of microglia per millimeter squared in the
hippocampus of TREM2+/+, n = 5 mice; P301S+ TREM2+/+, n = 9 mice; P301S+
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nostaining and the corresponding 3D reconstructions using Imaris. (Scale
bars: full-view images, 40 μm; magnified images, 20 μm.) (E) Quantification
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hoc analysis). Values are expressed as mean ± SEM.
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TREM2 have been shown to have lower levels of proinflammatory
markers (22), as well as reduced microglial density and a resting
state morphology. Together, these results, along with our RNA-
seq data (Figs. 2D and 3B and SI Appendix, Fig. S2B), suggest
inflammation as a possible mechanism by which TREM2 hap-
loinsufficiency vs. complete deficiency result in apparent op-
posing phenotypes, such as their effects on tau pathology.
Microglia have been implicated in the spread of tau pathology
(34), and their activation state could contribute to how they re-
spond in the context of tauopathy. Indeed, we found a significant
positive correlation between microglial density and tau pathol-
ogy (Fig. 6C).
Our surprising discovery that TREM2 haploinsufficiency ex-
erts a more robust impairment in microglial function and exac-
erbation of tau pathology compared with complete loss of
TREM2 highlights the plasticity of microglia in response to
TREM2 deficiency. The potential detrimental effects of TREM2
haploinsufficiency can provide insight into how TREM2 con-
tributes to AD pathogenesis and inform potential TREM2-
targeted therapeutic strategies.
Methods
Detailed procedures for all methods described here are provided in the
SI Appendix.
Mice.All animal procedures were carried out under protocols approved by the
University of California, San Francisco, Institutional Animal Care and Use
Committee.
In Vivo Imaging. Intravital imaging using two-photon microscopy was per-
formed with thinned-skull windows as previously described (24).
Antibodies, Immunohistochemistry, and Image Analysis. Immunohistochemis-
try and image analysis were performed by experimenters blinded to the
genotypes. The code was not broken until all analyses were completed.
Adult Microglia Isolation and Quantitative RT-PCR. Adult microglia were iso-
lated from TREM2+/+, TREM2+/− and TREM2−/−mice as described previously (35).
RNA-Seq and Analysis. RNA-seq libraries were prepared with Ovation RNA-seq
system v2 kit (NuGEN) or Lexogen QuantSeq 3′mRNA-Seq Library Prep Kit. All
RNA-seq data have been deposited in the Gene Expression Omnibus repository
(https://www.ncbi.nlm.nih.gov/geo/) under accession number GSE118630.
Statistical Analysis. Data were analyzed with GraphPad Prism v. 7 (GraphPad),
STATA12 (StataCorp), or R (R Foundation for Statistical Computing). Multilevel
mixed-effects linear regression model fit using STATA12 was used to compare
curves for young and aged mice in response to injury. For cluster analyses of
multiple measurements from individual mice, we used the R package lmer.
Outliers were removed based on GraphPad’s outlier analysis algorithm. All
animals were included for statistical analyses unless otherwise noted.
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